Opko Q2 FY26 net loss narrows to $8.4 million; revenue rises to $163.5 million - OPK News | RalliesOpko Q2 FY26 net loss narrows to $8.4 million; revenue rises to $163.5 million
O
OPK• Outlook
- Forecasts Q3 2026 total revenue of $131 million-$142 million; sees full-year total revenue of $560 million-$585 million.
Q2 revenue and loss details
- Opko Health Q2 2026 revenue rose 4.28% to $163.5 million; net loss narrowed to $8.4 million, or $0.01 per share.
- Operating loss improved to $7 million from $60 million a year earlier.
- Pharmaceuticals product revenue climbed to $42.9 million from $40.7 million, with Rayaldee revenue rising to $8.1 million from $7.2 million.
- IP and other revenue more than doubled to $46.1 million, driven by $29.4 million recognized from shares received under a Nicoya agreement amendment.
